Merger • Life Science

Larimar Therapeutics Acquires Zafgen

On May 29, 2020, Larimar Therapeutics acquired life science company Zafgen

Acquisition Context

This is Larimar Therapeutics’ 1st transaction in the Life Science sector.
This is Larimar Therapeutics’ 1st transaction in the United States.
This is Larimar Therapeutics’ 1st transaction in Massachusetts.

Explore All 191 Merger Life Science Deals - Search the Database Free

M&A Deal Summary
Date	May 29, 2020
Target	Zafgen
Sector	Life Science
Buyer(s)	Larimar Therapeutics
Deal Type	Merger

Target Company

Zafgen

Boston, Massachusetts, United States

Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen was founded in 2005 and is based in Boston, Massachusetts.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Larimar Therapeutics

Bala Cynwyd, Pennsylvania, United States

Category	Company
Sector	Life Science
Employees	65
Revenue	42M USD (2023)

DESCRIPTION

Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar Therapeutics is based in Bala Cynwyd, Pennsylvania.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Merger	1 of 1
State: Massachusetts	1 of 1
Country: United States	1 of 1
Year: 2020	1 of 1

Explore Related M&A Activity

Life Science M&A - Merger M&A Deals - Massachusetts M&A - United States M&A - 2020 M&A